STUDY DESIGN  Indefinite aspirin monotherapy has long been the standard after dual antiplatelet therapy (DAPT) in post-percutaneous coronary intervention (PCI) patients, but its benefits remain debated.1 Emerging but limited evidence suggests that clopidogrel may be a superior alternative, highligh

Lowering low-density lipoprotein cholesterol (LDL-C) levels is directly correlated with reducing the incidence of cardiovascular (CV) events.¹ Although statins can lower LDL-C levels, a significant number of patients do not reach the recommended LDL-C targets.² Introduction of proprotein

Ever since the United States Food and Drug Administration (FDA) issued the mandate for conducting cardiovascular outcomes trials (CVOTs) with type 2 diabetes drugs, eight CVOTs have already been completed,